Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 241 clinical trials
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or Metastatic Non

  • 0 views
  • 23 Jan, 2021
  • 4 locations
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).

  • 22 views
  • 25 Jan, 2021
  • 48 locations
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

This is a phase 2 single-arm, non-randomized multicentre and tissue acquisition study to evaluate acquired resistance mechanisms, efficacy, and safety in advanced, EGFR tyrosine kinase inhibitor

  • 3 views
  • 25 Jan, 2021
  • 1 location
A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2VEGFR3PDGFR and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to evaluate the efficacy

  • 0 views
  • 23 Jan, 2021
  • 1 location
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and inhibit tumor cell growth. We performed second-generation gene sequencing on

karnofsky performance status
neutrophil count
tumor progression
corticosteroids
measurable disease
  • 0 views
  • 23 Jan, 2021
  • 1 location
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

in subjects with advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations who have progressed while on treatment with an EGFR tyrosine kinase inhibitor (TKI) agent (other lines of

tyrosine
lung carcinoma
epidermal growth factor
alopecia
egfr t790m
  • 51 views
  • 30 Jan, 2021
  • 10 locations
A Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy (PONS).

This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a

  • 0 views
  • 23 Jan, 2021
  • 2 locations
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

called growth factors. Chronic myeloid leukemia cells need growth factors to grow and divide. The addition of ruxolitinib to the tyrosine kinase inhibitor may or may not help reduce the amount of chronic

  • 38 views
  • 03 Mar, 2021
  • 432 locations
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

, thus enhancing immune response and has potential to treat various types of tumors. As a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signalinganlotinib is

  • 1 views
  • 23 Jan, 2021
  • 1 location
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

experience significantly varying duration of response and survival rate. Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of

tyrosine
neutrophil count
recurrent non-small cell lung cancer
lung carcinoma
targeted therapy
  • 1 views
  • 23 Jan, 2021